医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2013年
9期
139-140
,共2页
复发性卵巢癌%托泊替康%顺铂
複髮性卵巢癌%託泊替康%順鉑
복발성란소암%탁박체강%순박
recurrent ovarian carcinoma(ROC)%topotecan(TPT)%cisplati(DDP)
目的:观察托泊替康联合顺铂治疗晚期复发性卵巢癌的疗效及毒副反应.方法:28例经病理或细胞学证实为晚期复发性卵巢癌患者予托泊替康0.75~1.2 mg/m2加入0.9%氯化钠100 ml中,静脉滴注30 min,d1-3;顺铂60~75 mg/m2加入0.9%氯化钠500 ml中,静脉滴注,dl.21 d为1周期,2周期为1疗程.结果:28例患者中CR 1例,PR 5例,SD 18例,PD 4例,总有效率为21.4%(6/28).毒副反应主要为骨髓抑制和脱发.结论:托泊替康联合顺铂是治疗晚期复发性卵巢癌疗效较好的方案.
目的:觀察託泊替康聯閤順鉑治療晚期複髮性卵巢癌的療效及毒副反應.方法:28例經病理或細胞學證實為晚期複髮性卵巢癌患者予託泊替康0.75~1.2 mg/m2加入0.9%氯化鈉100 ml中,靜脈滴註30 min,d1-3;順鉑60~75 mg/m2加入0.9%氯化鈉500 ml中,靜脈滴註,dl.21 d為1週期,2週期為1療程.結果:28例患者中CR 1例,PR 5例,SD 18例,PD 4例,總有效率為21.4%(6/28).毒副反應主要為骨髓抑製和脫髮.結論:託泊替康聯閤順鉑是治療晚期複髮性卵巢癌療效較好的方案.
목적:관찰탁박체강연합순박치료만기복발성란소암적료효급독부반응.방법:28례경병리혹세포학증실위만기복발성란소암환자여탁박체강0.75~1.2 mg/m2가입0.9%록화납100 ml중,정맥적주30 min,d1-3;순박60~75 mg/m2가입0.9%록화납500 ml중,정맥적주,dl.21 d위1주기,2주기위1료정.결과:28례환자중CR 1례,PR 5례,SD 18례,PD 4례,총유효솔위21.4%(6/28).독부반응주요위골수억제화탈발.결론:탁박체강연합순박시치료만기복발성란소암료효교호적방안.
Objective To evaluate the therapeutic and adverse effects of topotecan combined with cisplatin in the treatment of advanced recurrent ovarian cancer.Methods Totaly 28 patients with advanced recurrent ovarian cancer, which were confirmed by tissue pathology or cytopathology, were treated with intravenous infusion of topotecan at the dose of 0.75~1.2 mg/m2 (for 3 consecutive days)combined with intravenous infusion of cisplantin at 60~75 mg/m2 for one day. Each treatment course consisted of two 21-day cycles of the treatment. Results In these patients,1 patients had complete remission and 5 patients had partial remission,18 had clinicaly stabilized disease and 4 had progressive disease.The total response rate was 21.4%among the patients. The major adverse efects were bone marrow suppression and alopecia. Conclusion Topotecan plus cisplatin is a better regimen for the treatment of advanced recurrent ovarian cancer.
